Pharmacy Compounding Could Be Added To PDUFA III, APhA’s Winckler Says
Executive Summary
Pharmacy compounding could be revisited in the Prescription Drug User Fee Act if there is a Supreme Court decision before reauthorization is finalized, American Pharmaceutical Association Policy & Advocacy Group Director Susan Winckler said
You may also be interested in...
NACDS Interim Medicare Rx Plan: “OneCard” Plus Stop-Loss Coverage
The National Association of Chain Drug Stores is pushing its "OneCard" program as part of a two-prong interim legislative solution to help seniors afford prescription drugs in the absence of a Medicare Rx benefit
FDA Rx Compounding Ad Restrictions May Be Unnecessary, Justices Say
FDA restrictions on advertising compounded drugs may not be justified given the additional safeguards provided under the FDA Modernization Act, U.S. Supreme Court justices suggested during oral arguments in Thompson v. Western States Medical Center Feb. 26
Pharmacy Groups Exploring Medicare Rx Fallback Options
The retail pharmacy trade associations hope to reach an agreement on a fallback Medicare drug benefit proposal with a group of pharmaceutical manufacturers over the next month